128 results
424B5
IFRX
InflaRx N.V.
28 Jun 24
Prospectus supplement for primary offering
4:56pm
as of December 31, 2023 have been audited by EY GmbH & Co. KG Wirtschaftsprüfungsgesellschaft, independent registered public accounting firm, as set forth … shares and preferred shares are issued in registered form.
The preferred shares can be issued to an independent foundation under Dutch law
6-K
EX-99.1
IFRX
InflaRx N.V.
28 Jun 24
Leerink Partners LLC
4:55pm
in the Registration Statement and the Prospectus.
(s) Independent Accountants. Each accounting firm who have audited financial statements of the Company … , an independent registered public accounting firm with respect to the Company and its subsidiaries within the applicable rules and regulations adopted
6-K
EX-99.2
IFRX
InflaRx N.V.
5 Jun 24
InflaRx Hosts R&D Event Highlighting the Promise of INF904
5:07pm
research is reliable, such research has not been verified by any independent source. About InflaRx N.V. InflaRx (Nasdaq: IFRX) is a biopharmaceutical … Pathophysiology of the disease : Type I & IIb endotypes The role of C5a/C5aR signaling : IgE dependent and independent pathways The potential role of INF904
6-K
EX-99.1
IFRX
InflaRx N.V.
8 May 24
Report of Foreign Private Issuer
8:43am
acquisition bids, the Company`s general meeting of shareholders approved the right of an independent foundation under Dutch law, or protective foundation
6-K
EX-99.2
IFRX
InflaRx N.V.
8 May 24
Report of Foreign Private Issuer
8:43am
for the independent data safety monitoring committee), which is planned upon enrollment of approximately 30 patients, divided equally between the two arms … under agreements with CROs, contract manufacturing organizations, or CDMOs, consultants and independent contractors that conduct research
6-K
EX-99.1
b7ch95zlp0uer5is ap
4 Apr 24
Current report (foreign)
4:01pm
6-K
EX-99.1
mlrlw2 sbd
21 Mar 24
Corporate Presentation March 2024
5:00pm
6-K
EX-99.1
dbgiil7mu6g5nkl3pe
25 Jan 24
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
8:00am
6-K
EX-99.2
hzh5g zbtx
4 Jan 24
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
4:16pm
6-K
EX-99.1
hd1 u6839jx
6 Nov 23
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
8:00am
6-K
EX-99.1
x6qiwxq opxgc6r
1 Nov 23
Current report (foreign)
8:04am
6-K
EX-99.2
x7qzkck
1 Nov 23
Current report (foreign)
8:04am
6-K
EX-99.1
kqbv2w5dov
30 Aug 23
Current report (foreign)
8:00am
6-K
EX-99.2
0w4mrn
10 Aug 23
Report of Foreign Private Issuer
8:00am
6-K
EX-99.1
yf09yfz jxskkm
10 Aug 23
Report of Foreign Private Issuer
8:00am
424B5
hdolqneq1hba
12 Jul 23
Prospectus supplement for primary offering
12:00am
F-3
EX-4.3
rggt7vm
30 Jun 23
Shelf registration (foreign)
4:06pm
F-3
EX-5.1
baf7h7
30 Jun 23
Shelf registration (foreign)
4:06pm